SHR-4849 combined with other cancer drugs for malignant solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 interventional trial gives adults with histologically confirmed malignant solid tumors combinations that include SHR-4849 plus agents such as SHR-1316, SHR-8068, BP102, carboplatin, or cisplatin. Eligible participants must be 18–75 years old, have at least one measurable lesion per RECIST 1.1, an ECOG performance status of 0–1, and adequate organ function. The trial collects safety, tolerability, and preliminary efficacy data through scheduled clinical assessments and imaging across different combination cohorts. Exclusion criteria include active CNS metastases, recent other malignancies within five years, uncontrolled cancer pain, severe cardiovascular disease, and significant bleeding.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subject has provided informed consent prior to initiation of any study-procedures
2. Age from 18 to 75 years old at the time of signing the informed consent
3. Histologically or cytologically confirmed solid tumors
4. At least one measurable lesion was identified per RECIST 1.1
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
6. Has a life expectancy of at least 3 months.
7. Adequate organ function
8. Subjects of both genders of child-bearing potential were required to use highly effective contraception from the time they provided written informed consent until 8 months after the last dose of the trial drug

Exclusion Criteria:

1. Subjects with active central nervous system (CNS) metastasis.
2. Subjects with a history of malignant tumors within 5 years prior to the first dose
3. Subjects with uncontrolled cancer pain.
4. Subjects with severe cardiovascular disease.
5. Subjects with clinically significant hemorrhage
6. Subjects with uncontrolled pleural effusion, peritoneal effusion and pericardial effusion
7. Subjects highly suspected of interstitial lung disease
8. Subjects with serious infection within 4 weeks prior to the first dose
9. Known history of human immunodeficiency virus (HIV)，active hepatitis B virus or hepatitis C virus infection.
10. The adverse events of previous antineoplastic therapy did not recover to NCI-CTCAE≤ grade 1
11. Subjects who received anti-cancer treatment within 4 weeks prior to the first dose
12. Subjects who received major surgery within 4 weeks prior to the first dose
13. Subjects who plan to receive or have received live vaccines within 28 days prior to the first dose.
14. Female subjects who were pregnant, lactating, or planned to become pregnant during the study period
15. Known allergic to any component of investigational drugs
16. Alcohol abuse, drug abuse, other serious medical conditions (including mental illness) requiring combined treatment, and other conditions that may affect subject safety or data collection.
17. Based on the investigator's judgment, subjects with other conditions that may affect study results, interfere with study procedures,

Where it's running

• Affiliated Cancer Hospital of Shandong First Medical University
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: Wei Hou
• Email: wei.hou@hengrui.com
• Phone: 0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CAIX-targeted PET/CT imaging in solid tumors

  Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07833085

• TAK-505 treatment for adults with advanced solid tumors

  This trial will test TAK-505, an experimental drug, in adults with locally advanced or metastatic solid tumors (such as stomach, colorectal, non-small cell lung, and head and neck cancers) who have limited standard treatment options.

  Recruiting at 13 sites Phase 1/2 Takeda · Orange, California and 14 other locations · NCT07436728

• SHR-7787 combined with other anti-cancer drugs for malignant solid tumors

  This study will test whether giving SHR-7787 together with other anti-cancer medicines is safe and helps people with unresectable malignant solid tumors.

  Recruiting at 2 sites Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Wuhan, Hubei and 1 other locations · NCT07268040

• SHR-4298 Injection for Malignant Solid Tumors: a Phase I/II study

  This study tests SHR-4298 injections in adults with advanced solid tumors to see if it is safe, tolerable, and has signs of activity.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT07229612

• JCXH-211 injections with anti-PD-1 therapy for malignant solid tumors

  This study tests whether injecting JCXH-211 directly into tumors, together with an anti-PD-1 medicine, is safe and tolerable in adults with malignant solid tumors.

  Recruiting Phase 1/2 Immorna Biotherapeutics, Inc. · Guangzhou, Guangdong · NCT06781125

• Evaluating SHR-1681 for patients with advanced solid tumors

  This study is testing a new injection called SHR-1681 to see if it can safely help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT06737731

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.